Jim Simons
BTTX

Jim Simons’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Jim Simons’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,400
Closed -$14K – 4240
2023
Q2 		$14K Buy
+13,400
New +$13K ﹤0.01% 3811

Other funds holding BTTX

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CIAS
Capital Investment Advisory Services Raleigh, North Carolina $1.62B AUM 27.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Jim Simons's BTTX Position: Q3 2023 in Review

Jim Simons sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q3 2023, closing a stake of 13,400 shares — an estimated $14K sold.

Jim Simons first reported a position in BTTX in Q2 2023 and held it in 1 quarter. The position peaked at $14K in Q2 2023. 18 funds tracked by Wall St. Rank hold BTTX as of Q3 2023.

  • Jim Simons reported no remaining Better Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Jim Simons sold 13,400 Better Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $14K.
  • Jim Simons first reported a position in Better Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • Jim Simons's Better Therapeutics, Inc. Common Stock position peaked at $14K in Q2 2023.
  • 18 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Renaissance Technologies's 13F filing for Q3 2023, filed 14 Nov 2023.